)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Aclarion
Aclarion (ACON) investor relations material
Aclarion Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary5 Nov, 2026
Executive summary
Q3 revenue rose 78.1% YoY to $33,733, driven by higher Nociscan report volumes in the UK after local coverage decisions.
Nine-month revenue increased 39.9% YoY to $80,081, while net loss widened to $8.22M from $5.34M as operating expenses increased.
Financial highlights
Q3 gross profit was $14,796 versus $4,386; operating loss was $2.75M versus $1.83M, and net loss was $2.62M versus $1.71M.
9M gross profit was $26,843 versus $5,037; operating loss was $8.64M versus $5.06M, and net loss was $8.22M versus $5.34M.
Q3 operating expenses grew to $2.77M from $1.84M; 9M operating expenses rose to $8.67M from $5.06M.
Cash, cash equivalents and restricted cash were $14.21M at September 30, 2026, versus $12.04M at year-end 2025.
Outlook and guidance
Existing cash is expected to fund operating and capital requirements for at least 12 months from issuance of the financial statements; estimates depend on assumptions and additional capital may be needed.
Revenue is expected to increase as additional insurance payors are added and scan volumes grow; sales salaries are expected to remain elevated in Q4 2026.
R&D expense is expected to rise with Nociscan 3.0 development; CLARITY Trial expense is expected to increase as enrollment expands.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Aclarion
- Nociscan pairs spinal pain biomarkers with payer expansion and a funded outcomes trial.ACON
Corporate presentation - Nociscan pairs chemical disc diagnostics with a funded, outcomes-focused scale-up.ACONLD Micro 20th Annual Main Event Conference
- AI-driven NOCISCAN platform accelerates clinical and commercial growth in the global back pain market.ACONLytham Partners Fall 2026 Investor Conference
- Q2 2026 revenue rose 30.5% year-over-year, but net loss widened on higher operating costs.ACONQ2 2026
- AI-powered biomarkers may revolutionize spine surgery accuracy and payer adoption.ACONPlanet MicroCap Las Vegas 2026
- Revenue up 11% year-over-year, but net loss widened on higher expenses; cash supports growth plans.ACONQ1 2026
- Shareholders will vote on director elections, auditor ratification, and a major equity plan amendment.ACONProxy filing
- Shareholders will vote on director elections, auditor ratification, and a major equity plan amendment.ACONProxy filing
- Innovative MRI-based diagnostics for back pain gain traction with strong evidence and payer support.ACONPlanet MicroCap Showcase VEGAS 2025
Next Aclarion earnings date
Q4 202619 Feb, 2027
Aclarion
Next Aclarion earnings date
Q4 202619 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Aclarion Inc is a medical technology company that develops non-invasive diagnostic solutions for healthcare providers. The company focuses on integrating magnetic resonance spectroscopy with proprietary software to support clinical decision-making, particularly in the diagnosis of spinal disc-related disorders. Its technology is aimed at improving accuracy and efficiency in identifying sources of chronic back pain. Aclarion Inc is headquartered in Broomfield, Colorado, and its shares are listed on the NASDAQ.